Gaucher disease In Latin America. A report from the Gaucher Disease International Registry and the Latin Americam Group for Gaucher Disease

被引:0
|
作者
Drelichman, Guillermo [1 ]
Linares, Adriana [3 ]
Villalobos, Jacobo [2 ]
Francisco Cabello, Juan [4 ]
Kerstenetzky, Marcelo [5 ]
Kohan, Regina M. [6 ]
Martins, Ana Maria [7 ]
机构
[1] Hosp Ninos Dr Ricardo Gutierrez, Unidad Hematol, RA-1425 Buenos Aires, DF, Argentina
[2] Cent Univ Venezuela, Catedra Fisiol, Inst Expt Med, Caracas, Venezuela
[3] Univ Nacl Colombia, Bogota, Colombia
[4] Univ Chile, Lab Enfermedades Metab INTA, Santiago, Chile
[5] Hosp Barao de Lucena, Recife, PE, Brazil
[6] Hosp Ramos Mejia, Buenos Aires, DF, Argentina
[7] Univ Fed Sao Paulo, CREIM, Sao Paulo, Brazil
关键词
Gaucher disease; Latin America; lysosomal storage disease; ENZYME REPLACEMENT THERAPY; TYPE-1; MUTATION; HETEROGENEITY; CHILDREN; GOALS;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Gaucher disease In Latin America. A report from the Gaucher Disease International Registry and the Latin Americam Group for Gaucher Disease. Gaucher disease -due to its low frequency- is considered an orphan disease. In 1991 the International Gaucher Registry was created and in 1992 the first patients from Latin America were enrolled. In 2008 the Latin American Group for Gaucher Disease was initiated. Its main objectives are to promote regional consensus, to stimulate the enrolment of patients into the International Gaucher Registry and the enhancement of knowledge on this disease, and to achieve better care and quality of life of patients in our Region. Until April 2010, 5828 patients have been enrolled all around the world, 911 (15.6%) from Latin America. This is the first comprehensive report of the disease in the Region. In our population there is a predominance of females, the most common clinical form is the type I (95%) and the age at diagnosis is before 20 years in 68% of patients. The most frequent clinical manifestations at diagnosis are splenomegaly (96%) and anemia (49%). Eighty percent of patients had radiographic findings of bone involvement. In our Region, the vast majority of patients (89%) had received enzyme replacement therapy with imiglucerase; with a long follow-up (up to 10 years) they have achieved the therapeutic goals, showing the great effectiveness of therapy. While the percentage of patients with therapy is high, discontinuations are common. The main deficiencies in our Region are: the lack of visceral volumetric evaluations and densitometries as well as molecular analysis for some patients. The main problem is the under-diagnosis of patients.
引用
收藏
页码:273 / 282
页数:10
相关论文
共 50 条
  • [1] Supplement: Gaucher Disease Then and Now: Two Decades of Learning from the International Collaborative Gaucher Group Gaucher Registry Foreword
    Buyers, Rhonda P.
    Collin-Histed, Tanya
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 : S1 - S1
  • [2] Supplement: Gaucher Disease Then and Now: Two Decades of Learning from the International Collaborative Gaucher Group Gaucher Registry Afterword
    Grabowski, Gregory A.
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 : S29 - S29
  • [3] Long-term imiglucerase/alglucerase treatment in Latin American children with type 1 Gaucher disease: Lessons from the International Collaborative Gaucher Group (ICGG) Gaucher Registry
    Camelo, Jose, Jr.
    Cravo, Renata
    Cabello, Francisco
    Drelichman, Guillermo
    Kerstenetzky, Marcelo
    Sarmiento, Isabel
    Linares, Adriana
    MOLECULAR GENETICS AND METABOLISM, 2013, 108 (02) : S28 - S28
  • [4] Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry
    Rosenbloom, Barry E.
    Cappellini, Maria Domenica
    Weinreb, Neal J.
    Dragosky, Marta
    Revel-Vilk, Shoshana
    Batista, Julie L.
    Sekulic, Davorka
    Mistry, Pramod K.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (10) : 1337 - 1347
  • [5] A Report from the International Collaborative Gaucher Group (ICGG) Gaucher Registry
    vom Dahl, Stephan
    Cole, J. Alexander
    Weinreb, Neal J.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 : S225 - S226
  • [6] A Report from the International Collaborative Gaucher Group (ICGG) Gaucher Registry
    Weinreb, Neal J.
    Dahl, Stephan Vom
    BLOOD, 2008, 112 (11) : 1215 - 1215
  • [7] Gaucher disease and cancer incidence: a study from the Gaucher Registry
    Rosenbloom, BE
    Weinreb, NJ
    Zimran, A
    Kacena, KA
    Charrow, J
    Ward, E
    BLOOD, 2005, 105 (12) : 4569 - 4572
  • [8] The Gaucher registry -: Demographics and disease characteristics of 1698 patients with Gaucher disease
    Charrow, J
    Andersson, HC
    Kaplan, P
    Kolodny, EH
    Mistry, P
    Pastores, G
    Rosenbloom, BE
    Scott, CR
    Wappner, RS
    Weinreb, NJ
    Zimran, A
    ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (18) : 2835 - 2843
  • [9] Monoclonal gammopathies and hypergammaglobulemia in Gaucher disease: An analysis from the French Gaucher disease registry
    Nguyen, Yann
    Stirnemann, Jerome
    Monia, Bengherbia
    Yousfi, Karima
    Hamroun, Dalil
    Lautredoux, Florent
    Cador, Berengere
    Berger, Marc
    Fantin, Bruno
    Belmatoug, Nadia
    MOLECULAR GENETICS AND METABOLISM, 2019, 126 (02) : S107 - S107
  • [10] Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: A study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry
    Khan, Aneal
    Hangartner, Thomas
    Weinreb, Neal J.
    Taylor, John S.
    Mistry, Pramod K.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (08) : 1839 - 1848